Cargando…

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program

Case: The PIONEER phase 3 program investigated glycemic response and other efficacy endpoints in patients (pts) with type 2 diabetes randomized to the glucagon-like peptide-1 analog oral semaglutide (sema; 3, 7 or 14 mg once daily), placebo (pbo) or an active comparator (empagliflozin [empa] 25 mg,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, K B Sharan, Dungan, Kathleen M, Hertz, Christin L, Mellibin, Linda, Nielsen, Morten Abildlund, Sorrig, Rasmus, Woo, Vincent C, Vilsboll, Tina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Abstracts … Esicon 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067785/ http://dx.doi.org/10.4103/2230-8210.342129

Ejemplares similares

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial
por: Prakash, Prashanth S, et al.
Publicado: (2022)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program
por: Srivastava, Kunal, et al.
Publicado: (2022)

Abstract 129: Continuous glucose monitoring in type 2 diabetes mellitus to assess glycemic control and glycemic variability
Publicado: (2022)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Abstract 93: Ambulatory glucose profiles of children and adolescents with T1DM: Identification of factors affecting glycemic control
por: Tandon, Ambica, et al.
Publicado: (2022)

Abstract 137: Improved glycemic control among people with type 2 diabetes with a digital therapeutics approach in collaboration with clinicians
por: Singal, Arbinder, et al.
Publicado: (2022)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Abstract 98: Hirsutism under evaluation
por: Harshita, B, et al.
Publicado: (2022)

Abstract 4: Derived time-in-range is associated with major adverse cardiovascular event in T2D: Data from the DEVOTE trial
por: Pathan, Muzammil Khan A, et al.
Publicado: (2022)

Abstract 108: A case of familial acromegaly
por: Appaiah, Sonali, et al.
Publicado: (2022)

Abstract 79: Adrenal insufficiency in the elderly population
por: Joseph, Neal, et al.
Publicado: (2022)

Abstract 66: Spectrum of sleep abnormalities in primary hypothyroidism
por: Acharya, Himamshu, et al.
Publicado: (2022)

Abstract 113: Impact of COVID-19 on arterial stiffness
por: Sahay, Rakesh Kumar, et al.
Publicado: (2022)

Abstract 117: Uncommon presentation of a common disease
por: Shruthi, B
Publicado: (2022)

Abstract 51: Clinical profile of hypertension and diabetes in elderly
Publicado: (2022)

Abstract 33: Clinical exome sequencing in XY DSD
por: Das, Debaditya, et al.
Publicado: (2022)

Abstract 102: Case series of tumor induced osteomalacia
por: Mudalagiri, Manasa, et al.
Publicado: (2022)

Abstract 37: Adolescent primary hyperparathyroidism masquerading as rickets
por: Mathew, Anu
Publicado: (2022)

Abstract 60: Rickets in congenital bullous ichthyosiform erythroderma
por: Butukuri, Likhitha
Publicado: (2022)

Abstract 92: Contemporaneous association of pheochromocytoma with Cushing's syndrome
por: Acharya, Himamshu, et al.
Publicado: (2022)

Abstract 118: Primary hyperaldosteronism presenting as subarachnoid hemorrhage
por: Panikar, Krish, et al.
Publicado: (2022)

Abstract 107: Klinefelter's syndrome presenting with ambiguous genitalia
por: George, Belinda, et al.
Publicado: (2022)

Abstract 75: Prediction score for malignancy in thyroid nodule
por: Soumya, S, et al.
Publicado: (2022)

Abstract 159: Glomus tumour presenting with oncogenic osteomalacia
por: Mathew, Anu
Publicado: (2022)

Abstract 143: The tale of three ladies with thyrotoxic storms
por: Aswini, M, et al.
Publicado: (2022)

Abstract 125: Tropical hypopitutarism – Single centre experience
por: Kumar, EGA Lakshman, et al.
Publicado: (2022)

Abstract 90: Graves disease and parkinsonism: Is there a link?
por: Sourabh, Sagar, et al.
Publicado: (2022)

Abstract 36: Unusual presentions of primary infertility in females
por: Nalla, Smitha, et al.
Publicado: (2022)

Abstract 105: A case of transient neonatal thyrotoxicosis
por: Appaiah, Sonali, et al.
Publicado: (2022)

Abstract 8: Thyroid amyloidosis presenting as persistent painless thyroiditis
por: Prabhakar, Karthik, et al.
Publicado: (2022)

Abstract 94: Efficacy of cabergoline treatment in men with giant prolactinomas
Publicado: (2022)

Abstract 126: Myriad endocrine manifestations of a rare syndrome
por: Togarla, Srujana, et al.
Publicado: (2022)

Abstract 80: A case of familial growth hormone deficiency
por: Kulkarni, Deepa, et al.
Publicado: (2022)

Abstract 27: Neuropathy in primary hypothyroidism and response to thyroxine replacement
por: Muthukrishnan, J, et al.
Publicado: (2022)

Abstract 42: B-Lymphocyte subset distribution in patients with hyperprolactinemia
por: Shah, Moxit
Publicado: (2022)

Abstract 46: Karyotype and phenotype correlation in Turner syndrome in South India
por: Raja, B Rameez, et al.
Publicado: (2022)

Abstract 121: EFT in subclinical hypothyroidism and its correlation with various parameters
por: Sahu, Madhusmita, et al.
Publicado: (2022)

Abstract 156: Nutrition therapy: Evaluating relevant interactions for therapeutic success
por: Mahesh, D M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3bdhkjop0o5e5v7govf9pcvpgh